A 38-year-old man presents to his physician for follow-up after routine laboratory testing revealed persistently elevated liver enzymes. He immigrated to the United States from East Asia 5 years ago and has no significant medical history. He does not take any medications. He denies alcohol use. Physical examination is unremarkable. Laboratory studies demonstrate the following:
Abdominal ultrasound demonstrates no focal liver lesions or evidence of cirrhosis.
Which of the following is the most appropriate next step in management?
The correct answer is:
A) Begin antiviral therapy with tenofovir or entecavir
This patient has chronic hepatitis B infection with evidence of active viral replication and ongoing hepatic inflammation. The diagnosis of chronic hepatitis B is supported by the presence of HBsAg and total anti-HBc with a negative IgM anti-HBc, indicating infection lasting longer than 6 months. The elevated HBV DNA level, positive HBeAg, and elevated aminotransferases indicate active viral replication causing liver injury.
The primary goals of treatment are to suppress viral replication, reduce hepatic inflammation, prevent progression to cirrhosis, and decrease the risk of hepatocellular carcinoma (HCC). First-line therapy consists of potent nucleos(t)ide analogs with a high barrier to resistance, such as tenofovir or entecavir.
Step 2 commonly tests the distinction between chronic HBV infection and inactive carrier status. Patients with inactive chronic infection typically have low or undetectable HBV DNA levels, normal liver enzymes, and do not necessarily require immediate antiviral therapy. In contrast, this patient has active disease and meets criteria for treatment.
Another important board concept is that patients with chronic hepatitis B remain at risk for hepatocellular carcinoma even in the absence of cirrhosis. Therefore, many patients require ongoing HCC surveillance with periodic liver ultrasound.
Answer choice B: Reassure the patient that treatment is unnecessary, is incorrect.
This would be appropriate only for selected patients with inactive chronic HBV infection who have low viral loads and normal liver enzymes. This patient has active viral replication and ongoing hepatic inflammation.
Answer choice C: Repeat hepatitis B serologies in 10 years, is incorrect.
Delaying management would permit ongoing liver injury and increase the risk of cirrhosis and hepatocellular carcinoma. Patients with active chronic hepatitis B require treatment and monitoring.
Answer choice D: Start corticosteroid therapy, is incorrect.
Corticosteroids are not standard therapy for chronic hepatitis B and may actually worsen viral replication through immunosuppression.
Answer choice E: Vaccinate against hepatitis B, is incorrect.
Vaccination is used to prevent hepatitis B infection. This patient already has established chronic infection and therefore cannot benefit from vaccination.
Key Learning Point
Patients with chronic hepatitis B who have elevated HBV DNA levels and evidence of active liver inflammation should be treated with antiviral therapy such as tenofovir or entecavir to reduce the risk of cirrhosis and hepatocellular carcinoma.
